Recent developments with neuropeptide Y receptor antagonists

Trends in Pharmacological Sciences

Volumn 17, Issue 9, 1996, Pages 301-304

  Lundberg, Jan M ^a   Modin, Agnes ^c   Malmström, Rickard E ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; ANGIOTENSIN; N [1 [4 [[[[4 [(DIMETHYLAMINO)METHYL]CYCLOHEXYL]METHYL]AMINO]IMINOMETHYL]BENZYL] 2 OXO 2 (1 PYRROLIDINYL)ETHYL] ALPHA [(2 NAPHTHALENYLSULFONYL)AMINO]BENZENEPROPANAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y [31 LEUCINE 34 PROLINE]; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y2 RECEPTOR; NORADRENALIN; PHENYLEPHRINE; PROPRANOLOL; RECEPTOR SUBTYPE; RESERPINE; SR 120107A; UNCLASSIFIED DRUG;

ADRENERGIC TRANSMISSION; CARDIOVASCULAR SYSTEM; DRUG RECEPTOR BINDING; HUMAN; NERVE STIMULATION; PRIORITY JOURNAL; SHORT SURVEY; VASOCONSTRICTION;

EID: 0030248267     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(96)10032-8     Document Type: Short Survey

References (35)

1. 1 Lundberg, J. M. et al. (1982) Acta Physiol. Scand. 116, 477-480
2. 2 Gray, T. S. and Morley, J. E. (1986) Life Sci. 38, 389-401
3. 3 Lundberg, J. M., Franco-Cereceda, A., Hemsén, A., Lacroix, J. S. and Pernow, J. (1990) Fundam. Clin. Pharmacol. 4, 373-391
4. 4 Wahlestedt, C. and Reis, D. J. (1993) Annu. Rev. Pharmacol. Toxicol. 32, 309-352
5. 5 Gehlert, D. (1994) Life Sci. 55, 551-562
6. 6 Wahlestedt, C., Yanaihara, N. and Håkanson, R. (1986) Regul. Pept. 13, 307-318
7. 7 Doods, H. N. and Krause, J. (1991) Eur. J. Pharmacol. 204, 101-103
8. 8 Modin, A., Pernow, J. and Lundberg, J. M. (1991) Eur. J. Pharmacol. 203, 165-171
9. 9 Lundberg, J. M. et al. (1988) Neuroscience 24, 659-672
10. 10 Herzog, H. et al. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5794-5798
11. 11 Larhammar, D. et al. (1992) J. Biol. Chem. 267, 10935-10938
12. 12 Rose, P. M. et al. (1995) J. Biol. Chem. 270, 22661-22664
13. 13 Higushi, H., Costa, E. and Yan, H-T. (1988) J. Pharmacol. Exp. Ther. 244, 468-474
14. 14 Jacques, D., Cadieux, A., Dumont, Y. and Quirion, R. (1995) Eur. J. Pharmacol. 278, R3-R5
15. 15 Lundberg, J. M. (1996) Pharmacol. Rev. 48, 113-178
16. 16 Bard, J. A., Walker, M. W., Branchek, T. A. and Weinshank, R. L. (1995) The Physiologist 38, A246
17. 17 Berglund, M. M. et al. (1995) The Physiologist 38, A249
18. 18 Weinberg, D. H. et al. J. Biol. Chem. (in press)
19. 19 Tseng, A., Inglis, A., Selbie, L. A., Moriarty, M. and Potter, E. K. (1994) Eur. J. Pharmacol. 271, 265-271
20. 20 Daniels, A. J. et al. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9067-9071
21. 21 Doods, H. N. et al. (1995) J. Pharmacol. Exp. Ther. 275, 136-142
22. 22 Grundemar, L. and Håkanson, R. (1991) Br. J. Pharmacol. 104, 776-778
23. 23 Mousli, M., Trifilieff, A., Pelton, J. T., Gies, J-P. and Landry, Y. (1995) Eur. J. Pharmacol. Mol. Pharmacol. Sect. 289, 125-133
24. 24 Rudolf, K. et al. (1994) Eur. J. Pharmacol. 271, R11-R13
25. 25 Serradeil-Le Gal, C. et al. (1994) Soc. Neurosci. Abstr. 20, 907
26. 26 Serradeil-Le Gal, C. et al. (1995) FEBS Lett. 362, 192-196
27. 27 Lundberg, J. M. and Modin, A. (1995) Br. J. Pharmacol. 116, 2971-2982
28. 28 Entzeroth, M. et al. (1995) Eur. J. Pharmacol. 278, 239-242
29. 29 Malmström, R. E., Modin, A. and Lundberg, J. M. (1996) Eur. J. Pharmacol. 305, 145-154
30. 30 Lundberg, J. M. and Tatemoto, K. (1982) Acta Physiol. Scand. 116, 393-402
31. 31 Morris, J. L. (1991) Regul. Pept. 32, 297-310
32. 32 Malmström, R. E. and Lundberg, J. M. (1995) Acta Physiol. Scand. 155, 329-330
33. 33 Malmström, R. E. and Lundberg, J. M. (1995) Eur. J. Pharmacol. 294, 661-668
34. 34 Schalling, M. et al. (1991) Neuroscience 41, 753-766
35. 35 Zukowska-Grojec, Z., Dayao, E. K., Karwatowska-Prokopczuk, E., Hauser, G. J. and Doods, H. N. (1996) Am. J. Physiol. 270, H796-H800